ATE17189T1 - 5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe. - Google Patents

5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe.

Info

Publication number
ATE17189T1
ATE17189T1 AT82902190T AT82902190T ATE17189T1 AT E17189 T1 ATE17189 T1 AT E17189T1 AT 82902190 T AT82902190 T AT 82902190T AT 82902190 T AT82902190 T AT 82902190T AT E17189 T1 ATE17189 T1 AT E17189T1
Authority
AT
Austria
Prior art keywords
oral dosage
dosage form
release oral
anionic polymer
intestinal juice
Prior art date
Application number
AT82902190T
Other languages
English (en)
Inventor
John Rhodes
Brian Kenneth Evans
Original Assignee
Tillott J B Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10523624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE17189(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillott J B Ltd filed Critical Tillott J B Ltd
Application granted granted Critical
Publication of ATE17189T1 publication Critical patent/ATE17189T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT82902190T 1981-07-31 1982-07-28 5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe. ATE17189T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8123573 1981-07-31
PCT/GB1982/000235 WO1983000435A1 (en) 1981-07-31 1982-07-28 Orally administrable pharmaceutical compositions
EP82902190A EP0097651B1 (de) 1981-07-31 1982-07-28 5-asa enthaltende orale verabreichungsform mit verzögerter wirkstofffreigabe

Publications (1)

Publication Number Publication Date
ATE17189T1 true ATE17189T1 (de) 1986-01-15

Family

ID=10523624

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82902190T ATE17189T1 (de) 1981-07-31 1982-07-28 5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe.

Country Status (14)

Country Link
US (2) US5541170A (de)
EP (1) EP0097651B1 (de)
JP (1) JPS58501174A (de)
AT (1) ATE17189T1 (de)
AU (1) AU551173B2 (de)
CA (1) CA1172570A (de)
DE (1) DE3268277D1 (de)
DK (1) DK158931C (de)
FI (1) FI85216C (de)
GB (1) GB2123695B (de)
IT (1) IT1149328B (de)
NO (1) NO159696C (de)
WO (1) WO1983000435A1 (de)
ZA (1) ZA825384B (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
JPS57500432A (de) * 1980-03-20 1982-03-11
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
DE3775880D1 (de) * 1986-09-18 1992-02-20 London School Of Pharmacy Innovations Ltd., London, Gb
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
JPH01299226A (ja) * 1988-05-27 1989-12-04 Seikagaku Kogyo Co Ltd サラゾスルファピリジン腸溶顆粒
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
US5032405A (en) * 1989-09-27 1991-07-16 Warner-Lambert Company Oral pharmaceutical composition for acid sensitive proteinaceous agents
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
JPH05507948A (ja) * 1990-04-18 1993-11-11 ユニバーシティ オブ ユタ リサーチ ファウンデーション アゾ結合を含み、ｐＨ依存性膨潤を示す、架橋したヒドロゲルに基づいた、結腸を標的にした経口薬の投薬形態
GB2253346A (en) * 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
NL9002336A (nl) * 1990-10-24 1992-05-18 Leuven K U Res & Dev Bekledings- of matrixmateriaal voor geneesmiddelen.
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
AU1587392A (en) * 1991-03-15 1992-10-21 Norwich Eaton Pharmaceuticals, Inc. The use of 5-aminosalicylic acid in the treatment of irritable bowel syndrome - diarrheal phase or type (ibs-d)
CA2148465C (en) * 1992-11-06 1999-11-02 Minenobu Okayama Oral pharmaceutical preparation releasable in the lower digestive tract
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
ES2149250T3 (es) * 1993-04-23 2000-11-01 Novartis Ag Dispositivo para la administracion de medicamentos con liberacion controlada.
DK66493D0 (da) * 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
SE9401738D0 (sv) * 1994-05-19 1994-05-19 Ewos Ab Bioactive feed
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
GB2303550B (en) * 1994-06-21 1998-07-08 Danbiosyst Uk Colonic drug delivery system
US5637319A (en) * 1995-03-01 1997-06-10 Takada; Kanji Controlled-release preparations
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
US6156340A (en) * 1996-03-29 2000-12-05 Duquesne University Of The Holy Ghost Orally administrable time release drug containing products
AU2521797A (en) * 1996-04-12 1997-11-07 Japan Atomic Energy Research Institute Ph-sensitive polymers
GB9620709D0 (en) * 1996-10-04 1996-11-20 Danbiosyst Uk Colonic delivery of weak acid drugs
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
EP1101490B1 (de) 1998-07-28 2005-04-13 Tanabe Seiyaku Co., Ltd. Zur wirkstoffabgabe an zielorten im darm fähige zubereitung
AU5654699A (en) * 1998-09-21 2000-04-10 Amato Pharmaceutical Products, Ltd. Oral drug delivery system for enhancing the bioavailability of activated glycyrrhetin
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
IT1303753B1 (it) * 1998-11-13 2001-02-23 Ct Lab Farm Srl Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici.
NZ513037A (en) 1999-01-29 2003-05-30 Disphar Internat B Coated sustained release pharmaceutical composition for the release of an agent in the gastrointestinal tract
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
CN1173695C (zh) 1999-06-14 2004-11-03 科斯默股份公司 控制释放与掩蔽味道的口服药物组合物
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6620834B1 (en) 1999-07-02 2003-09-16 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20030114349A1 (en) * 2000-04-27 2003-06-19 The Procter & Gamble Company Coating composition for solid bodies
IL153514A0 (en) 2000-06-21 2003-07-06 Cubist Pharm Inc Compositions and methods to improve the oral absorption of antimicrobial agents
TWI249519B (en) 2000-08-29 2006-02-21 Nobex Corp Immunoregulatory compounds and derivatives and methods of treating diseases therewith
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
US20070059368A1 (en) * 2005-05-31 2007-03-15 Cherukuri S R Modified release formulations of anti-irritability drugs
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US8282955B2 (en) * 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
US20070042143A1 (en) * 2003-04-23 2007-02-22 Ferring B.V. Sachet for a pharmaceutical composition
CN1972698B (zh) 2003-09-01 2010-06-02 有限会社爱泽世 β-羟基短-中链脂肪酸聚合物
US7825106B2 (en) 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
AU2004314731B2 (en) * 2004-01-20 2011-07-07 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
EP2361620B1 (de) 2004-02-06 2016-04-06 PHARMATEL (R&D) PTY LIMITED as Trustee for the PHARMATEL (R & D) TRUST Verwendung von aminosalicylaten beim reizdarmsyndrom mit durchfall als vorherrschendem symptom
KR20130028807A (ko) * 2004-05-28 2013-03-19 샐릭스 파마슈티컬스 인코포레이티드 방사선 유발성 장염의 예방, 치료 및 개선 방법
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
ATE424189T1 (de) * 2004-09-01 2009-03-15 Procter & Gamble Zusammensetzungen mit 5-amino-2- hydroxybenzoesäure und einem reduzierendem zucker
US9149439B2 (en) * 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US20090017110A1 (en) * 2005-05-31 2009-01-15 Capricorn Pharma Inc. Modified release formulations of anti-irritability drugs
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102670626A (zh) * 2005-08-24 2012-09-19 萨利克斯药品公司 巴柳氮制剂及其生产和应用
US7964215B1 (en) 2006-01-24 2011-06-21 Emet Pharmaceuticals, LLC Delayed release dosage form
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
US20110144188A1 (en) * 2006-06-06 2011-06-16 Antibe Therapeutics Inc. Salts of trimebutine and n-desmethyl trimebutine
BRPI0622008A2 (pt) * 2006-09-13 2011-12-20 Procter & Gamble métodos de tratamento para colite ulcerativa
AU2006348138A1 (en) * 2006-09-13 2008-03-20 Warner Chilcott Company, Llc Methods of treatment for ulcerative colitis using aminosalicylate
WO2008085484A2 (en) * 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
US20090028944A1 (en) * 2007-07-16 2009-01-29 Balaji Sathurappan Pharmaceutical compositions comprising mesalamine
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
US20090162434A1 (en) * 2007-12-21 2009-06-25 Disphar International Bv Mesalazine tablet
US20090169622A1 (en) * 2007-12-27 2009-07-02 Roxane Laboratories, Inc. Delayed-release oral pharmaceutical composition for treatment of colonic disorders
NZ592049A (en) * 2008-10-03 2012-11-30 Falk Pharma Gmbh Compositions and methods for the treatment of bowel diseases with granulated mesalamine
ES2641471T3 (es) 2008-10-06 2017-11-10 The Johns Hopkins University Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos
US9463163B2 (en) 2009-10-16 2016-10-11 Sun Pharmaceutical Industries Limited Delayed release pharmaceutical composition of mesalamine
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
RU2014141201A (ru) 2012-03-29 2016-05-20 ТЕРАБАЙОМ, ЭлЭлСи Композиции для желудочно-кишечной сайт-специфической пероральной вакцинации, проявляющие активность в подвздошной кишке и аппендиксе
US20140066837A1 (en) 2012-07-26 2014-03-06 Ronald L. Moy Skin care compositions and methods
US20140141075A1 (en) 2012-11-21 2014-05-22 Warner Chilcott Company, Llc 5-aminosalicylic acid capsule formulation
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
JP6294457B2 (ja) 2013-03-15 2018-03-14 ワーナー チルコット カンパニー， エルエルシーＷａｒｎｅｒ Ｃｈｉｌｃｏｔｔ Ｃｏｍｐａｎｙ， Ｌｌｃ 低減した送達変動性のための複数の投薬要素を備えるメサラミン医薬組成物
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
CN117815373A (zh) 2013-04-07 2024-04-05 博德研究所 用于个性化瘤形成疫苗的组合物和方法
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
RU2733754C2 (ru) 2015-05-20 2020-10-06 Те Брод Инститьют Инк. Общие неоантигены
CA3133710C (en) 2015-11-02 2023-10-24 Pura Scents, Inc. Scent dispensation
USD809116S1 (en) 2015-11-02 2018-01-30 Pura Scents Dispenser
USD816506S1 (en) 2015-11-02 2018-05-01 Pura Scents, Inc. Vial for a scent dispenser
EP3446119A1 (de) 2016-04-18 2019-02-27 The Broad Institute Inc. Verbesserte hla-epitopvorhersage
EP3257501A1 (de) 2016-06-14 2017-12-20 Tillotts Pharma AG Aus mehreren einzeleinheiten zusammengesetzte dosierungsform mit einem kern aus individuellen kerneinheiten, die mit mukoadhäsivem material bedeckt sind, sowie einer enterischen kernbeschichtung
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US10098898B1 (en) 2017-12-04 2018-10-16 Handa Pharmaceuticals, Llc Release stable mesalamine dosage forms
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
CN116249774A (zh) 2020-05-26 2023-06-09 迪奥尼斯治疗公司 核酸人工微型蛋白质组文库
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1204363B (de) * 1963-09-10 1965-11-04 Hoffmann La Roche Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt
US3935326A (en) * 1967-06-28 1976-01-27 Boehringer Mannheim G.M.B.H. Process for coating tablets with aqueous resin dispersions
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
PH10958A (en) * 1967-08-18 1977-10-13 Abbott Lab Tablet preparation
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
US3784683A (en) * 1971-03-29 1974-01-08 Abbott Lab Tablet preparation
US3954959A (en) * 1973-03-28 1976-05-04 A/S Alfred Benzon Oral drug preparations
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
GB2021409B (en) * 1977-05-25 1982-09-22 Fisons Ltd Pharmaceutical composition
US4190716A (en) * 1978-12-20 1980-02-26 Dynapol Polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
JPS57500432A (de) * 1980-03-20 1982-03-11
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap

Also Published As

Publication number Publication date
JPH0414083B2 (de) 1992-03-11
DK128283D0 (da) 1983-03-21
CA1172570A (en) 1984-08-14
WO1983000435A1 (en) 1983-02-17
DK158931C (da) 1990-12-31
NO159696B (no) 1988-10-24
EP0097651B1 (de) 1986-01-02
JPS58501174A (ja) 1983-07-21
FI85216B (fi) 1991-12-13
DK128283A (da) 1983-03-21
GB2123695A (en) 1984-02-08
GB8322387D0 (en) 1983-09-21
US5541170A (en) 1996-07-30
FI833099A0 (fi) 1983-08-31
AU8732482A (en) 1983-02-22
NO830948L (no) 1983-03-17
EP0097651A1 (de) 1984-01-11
NO159696C (no) 1989-02-01
IT1149328B (it) 1986-12-03
GB2123695B (en) 1985-05-01
FI85216C (fi) 1992-03-25
DE3268277D1 (en) 1986-02-13
US5541171A (en) 1996-07-30
AU551173B2 (en) 1986-04-17
IT8248908A0 (it) 1982-07-29
DK158931B (da) 1990-08-06
FI833099A (fi) 1983-08-31
ZA825384B (en) 1983-05-25

Similar Documents

Publication Publication Date Title
ATE17189T1 (de) 5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe.
KR930702963A (ko) 장질환 치료를 위한 서방성 경구 투약 형태
FI823975A0 (fi) Farmaceutisk flerenhetssammansaettning
IL118240A (en) Oral coated capsule dosage form of omega-3 polyunsaturated acid for release of the acid in the intestine
KR970058705A (ko) 포접화합물을 함유한 부위특이적 방출성 제제
KR880007066A (ko) 우라피딜의 약제 형태